Erste Group Bank Analysts Raise Earnings Estimates for Roche

Roche Holding AG (OTCMKTS:RHHBY) – Research analysts at Erste Group Bank boosted their FY2026 earnings estimates for Roche in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.14 for the year, up from their prior forecast of $3.12. The consensus estimate for Roche’s current full-year earnings is $3.13 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.37 EPS.

A number of other equities analysts have also recently issued reports on RHHBY. Morgan Stanley raised Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price for the company in a report on Friday, April 24th. Zacks Research lowered Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Argus upgraded Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Finally, HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Roche has an average rating of “Hold” and a consensus target price of $51.50.

Roche Trading Up 0.3%

OTCMKTS RHHBY opened at $51.14 on Monday. The firm’s fifty day moving average price is $51.34 and its two-hundred day moving average price is $52.68. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche has a fifty-two week low of $37.51 and a fifty-two week high of $60.85.

Institutional Investors Weigh In On Roche

A number of institutional investors have recently modified their holdings of RHHBY. McIlrath & Eck LLC acquired a new stake in shares of Roche during the first quarter worth $39,000. Oakworth Capital Inc. lifted its holdings in Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after buying an additional 285 shares during the period. Atlas Capital Advisors Inc. bought a new stake in Roche during the fourth quarter valued at $192,000. Albert D Mason Inc. bought a new stake in Roche during the fourth quarter valued at $207,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new stake in Roche during the 1st quarter worth about $208,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.